Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

被引：87
作者：
Jaaskelainen, Anne J. [1 ,2 ]
Kekalainen, Eliisa [1 ,2 ]
Kallio-Kokko, Hannimari [1 ,2 ]
Mannonen, Laura [1 ,2 ]
Kortela, Elisa [2 ,3 ]
Vapalahti, Olli [1 ,2 ]
Kurkela, Satu [1 ,2 ]
Lappalainen, Maija [1 ,2 ]
机构：
[1] Univ Helsinki, Dept Virol, Helsinki, Finland
[2] Helsinki Univ Hosp, Helsinki, Finland
[3] Univ Helsinki, Infect Dis, Helsinki, Finland
来源：
EUROSURVEILLANCE | 2020年 / 25卷 / 18期
关键词：
D O I：
10.2807/1560-7917.ES.2020.25.18.2000603
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lubeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.
引用
收藏
页码：11 / 18
页数：8
相关论文
共 13 条
  • [1] Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]
  • [2] [Anonymous], 2020, LAB TEST 2019 NOV CO
  • [3] Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (Publication with Expression of Concern)
    Corman, Victor M.
    Landt, Olfert
    Kaiser, Marco
    Molenkamp, Richard
    Meijer, Adam
    Chu, Daniel K. W.
    Bleicker, Tobias
    Bruenink, Sebastian
    Schneider, Julia
    Schmidt, Marie Luisa
    Mulders, Daphne G. J. C.
    Haagmans, Bart L.
    van der Veer, Bas
    van den Brink, Sharon
    Wijsman, Lisa
    Goderski, Gabriel
    Romette, Jean-Louis
    Ellis, Joanna
    Zambon, Maria
    Peiris, Malik
    Goossens, Herman
    Reusken, Chantal
    Koopmans, Marion P. G.
    Drosten, Christian
    [J]. EUROSURVEILLANCE, 2020, 25 (03) : 23 - 30
  • [4] ECDC, 2020, Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - tenth update
  • [5] Eurosurveillance editorial team, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.6.2002131
  • [6] Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020
    Haveri, Anu
    Smura, Teemu
    Kuivanen, Suvi
    Osterlund, Pamela
    Hepojoki, Jussi
    Ikonen, Niina
    Pitkapaasi, Marjaana
    Blomqvist, Soile
    Ronkko, Esa
    Kantele, Anu
    Strandin, Tomas
    Kallio-Kokko, Hannimari
    Mannonen, Laura
    Lappalainen, Maija
    Broas, Markku
    Jiang, Miao
    Siira, Lotta
    Salminen, Mika
    Puumalainen, Taneli
    Sane, Jussi
    Melin, Merit
    Vapalahti, Olli
    Savolainen-Kopra, Carita
    [J]. EUROSURVEILLANCE, 2020, 25 (11) : 16 - 21
  • [7] Lepore L, 2020, EUROSURVEILLANCE, V25, DOI 10.2807/1560-7917.ES. 2020.25.11.2000230
  • [8] Okba NMA, 2019, EMERG INFECT DIS, V25, P1868, DOI [10.3201/eid2509.190051, 10.3201/eid2510.190051]
  • [9] Okba NMA, SARS COV 2 SPECIFIC, DOI [10.1101/2020.03.17.20037748, DOI 10.1101/2020.03.17.20037748]
  • [10] COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal
    Siddiqi, Hasan K.
    Mehra, Mandeep R.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (05) : 405 - 407
12